Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Memorial Sloan Kettering Cancer Center · Sarah Cannon · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
550
total citations
- FWCI
- 31.91
- Percentile
- 100%
- References
- 13
Citations per year
Authors
23Topics & keywords
Topics
Keywords
- Medicine
- Regimen
- Clinical endpoint
- Lung cancer
- Internal medicine
- Cancer
- Phases of clinical research
- Gastroenterology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.